*Adjusted by hospital group

** Adjusted by hospital group and previous infection status

*** Adjusted VE could not be calculated

Table 3 . Two-dose CoronaVac effectiveness against symptomatic PCR-confirmed COVID-19 infection for entire cohort for total study period, and for Delta-predominant period only, by time since receipt of second vaccine, Azerbaijan, 2021.